287 related articles for article (PubMed ID: 34731351)
1. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.
Poggio F; Del Mastro L; Bruzzone M; Ceppi M; Razeti MG; Fregatti P; Ruelle T; Pronzato P; Massarotti C; Franzoi MA; Lambertini M; Tagliamento M
Breast Cancer Res Treat; 2022 Jan; 191(2):269-275. PubMed ID: 34731351
[TBL] [Abstract][Full Text] [Related]
2. The oncologic impact of hormone replacement therapy in premenopausal breast cancer survivors: A systematic review.
Wang Y; Lewin N; Qaoud Y; Rajaee AN; Scheer AS
Breast; 2018 Aug; 40():123-130. PubMed ID: 29763858
[TBL] [Abstract][Full Text] [Related]
3. Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: A systematic review and meta-analysis.
Mudhune GH; Armour M; McBride KA
Breast; 2019 Oct; 47():43-55. PubMed ID: 31344603
[TBL] [Abstract][Full Text] [Related]
4. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
Li D; Ding CY; Qiu LH
Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
[TBL] [Abstract][Full Text] [Related]
5. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis.
Shim SH; Lee SJ; Kim SN
Eur J Cancer; 2014 Jun; 50(9):1628-37. PubMed ID: 24685478
[TBL] [Abstract][Full Text] [Related]
6. The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue.
Ruan X; Mueck AO
Horm Mol Biol Clin Investig; 2018 Aug; 37(1):. PubMed ID: 30120909
[TBL] [Abstract][Full Text] [Related]
7. Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.
Kim S; Ko Y; Lee HJ; Lim JE
Breast Cancer Res Treat; 2018 Aug; 170(3):667-675. PubMed ID: 29713854
[TBL] [Abstract][Full Text] [Related]
8. Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis.
Coronado PJ; Gómez A; Iglesias E; Fasero M; Baquedano L; Sánchez S; Ramírez-Polo I; de la Viuda E; Otero B; Llaneza P; Mendoza N; Lubián DM;
Menopause; 2024 Mar; 31(3):234-242. PubMed ID: 38385734
[TBL] [Abstract][Full Text] [Related]
9. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy.
Bundred NJ; Kenemans P; Yip CH; Beckmann MW; Foidart JM; Sismondi P; Schoultz Bv; Vassilopoulou-Sellin R; Galta RE; Lieshout EV; Mol-Arts M; Planellas J; Kubista E
Breast Cancer Res; 2012 Jan; 14(1):R13. PubMed ID: 22251615
[TBL] [Abstract][Full Text] [Related]
10. Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.
Deli T; Orosz M; Jakab A
Pathol Oncol Res; 2020 Jan; 26(1):63-78. PubMed ID: 30617760
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea.
Baek JK; Kim HI; Kang MJ; Seon KE; Kim EH; Seo SK
Climacteric; 2022 Oct; 25(5):516-522. PubMed ID: 35674251
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.
Fahlén M; Fornander T; Johansson H; Johansson U; Rutqvist LE; Wilking N; von Schoultz E
Eur J Cancer; 2013 Jan; 49(1):52-9. PubMed ID: 22892060
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy in breast cancer patients and survivors.
Del Priore G; Hatami M
Curr Womens Health Rep; 2003 Apr; 3(2):165-9. PubMed ID: 12628087
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy in women with a history of breast cancer.
Ylikorkala O; Metsä-Heikkilä M
Gynecol Endocrinol; 2002 Dec; 16(6):469-78. PubMed ID: 12626034
[TBL] [Abstract][Full Text] [Related]
15. Hormone Replacement Therapy After Breast Cancer: It Is Time.
Bluming AZ
Cancer J; 2022 May-Jun 01; 28(3):183-190. PubMed ID: 35594465
[TBL] [Abstract][Full Text] [Related]
16. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped.
Holmberg L; Anderson H;
Lancet; 2004 Feb; 363(9407):453-5. PubMed ID: 14962527
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates.
Beckmann MW; Jap D; Djahansouzi S; Nestle-Krämling C; Kuschel B; Dall P; Brumm C; Bender HG
Oncology; 2001; 60(3):199-206. PubMed ID: 11340370
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.
Col NF; Hirota LK; Orr RK; Erban JK; Wong JB; Lau J
J Clin Oncol; 2001 Apr; 19(8):2357-63. PubMed ID: 11304788
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.
Krul IM; Opstal-van Winden AWJ; Aleman BMP; Janus CPM; van Eggermond AM; De Bruin ML; Hauptmann M; Krol ADG; Schaapveld M; Broeks A; Kooijman KR; Fase S; Lybeert ML; Zijlstra JM; van der Maazen RWM; Kesminiene A; Diallo I; de Vathaire F; Russell NS; van Leeuwen FE
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):843-853. PubMed ID: 28888722
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study.
Jiang Y; Xie Q; Chen R
Clin Breast Cancer; 2022 Feb; 22(2):e206-e213. PubMed ID: 34548240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
